Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer

Concetta De Cicco, Laura Ravasi, Laura Zorzino, Maria Teresa Sandri, Edoardo Botteri, Fabrizio Verweij, Donatella Granchi, Ottavio De Cobelli, Giovanni Paganelli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of patients if pre-surgical identification were available. Material and Methods: Correlations between pre-surgical levels of 6 blood molecules and pathological tumour staging, post-surgical Gleason score and disease-free survival have been observed. Plasma and sera from 162 men affected by prostate adenocarcinoma were analysed with ELISA to assess levels of neovascularization-related molecule (VEGF), endothelial cell adhesion molecule (VCAM), extracellular matrix destruction-related molecules (MMP-2, MMP-9), and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2). Results: The median values of serum determinations were for VEGF 279 pg/ml, VCAM 633 ng/ml, MMP-2 206 ng/ml and MMP-9 614 ng/ml. Plasma medians (ng/ml) were 94 for TIMP-1 and 90 for TIMP-2. Patients with VCAM values > 633 ng/ml had a worse disease-free survival than patients with values

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalCurrent Cancer Drug Targets
Volume8
Issue number3
DOIs
Publication statusPublished - May 2008

Fingerprint

Cell Adhesion Molecules
Matrix Metalloproteinases
Vascular Endothelial Growth Factor A
Tissue Inhibitor of Metalloproteinase-1
Prostatic Neoplasms
Endothelial Cells
Tissue Inhibitor of Metalloproteinase-2
Disease-Free Survival
Prostate
Adenocarcinoma
Phenotype
Neoplasm Grading
Neoplasm Staging
Serum
Extracellular Matrix
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis
Bone and Bones

Keywords

  • Blood marker
  • Bone metastasis
  • MMP
  • MMP-2
  • Prognosis
  • Prostate cancer
  • TIMP
  • VCAM
  • VEGF

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research

Cite this

Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer. / De Cicco, Concetta; Ravasi, Laura; Zorzino, Laura; Sandri, Maria Teresa; Botteri, Edoardo; Verweij, Fabrizio; Granchi, Donatella; De Cobelli, Ottavio; Paganelli, Giovanni.

In: Current Cancer Drug Targets, Vol. 8, No. 3, 05.2008, p. 199-206.

Research output: Contribution to journalArticle

@article{3acbcc1b16ef498ea23b9d6720fb8c30,
title = "Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer",
abstract = "Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of patients if pre-surgical identification were available. Material and Methods: Correlations between pre-surgical levels of 6 blood molecules and pathological tumour staging, post-surgical Gleason score and disease-free survival have been observed. Plasma and sera from 162 men affected by prostate adenocarcinoma were analysed with ELISA to assess levels of neovascularization-related molecule (VEGF), endothelial cell adhesion molecule (VCAM), extracellular matrix destruction-related molecules (MMP-2, MMP-9), and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2). Results: The median values of serum determinations were for VEGF 279 pg/ml, VCAM 633 ng/ml, MMP-2 206 ng/ml and MMP-9 614 ng/ml. Plasma medians (ng/ml) were 94 for TIMP-1 and 90 for TIMP-2. Patients with VCAM values > 633 ng/ml had a worse disease-free survival than patients with values",
keywords = "Blood marker, Bone metastasis, MMP, MMP-2, Prognosis, Prostate cancer, TIMP, VCAM, VEGF",
author = "{De Cicco}, Concetta and Laura Ravasi and Laura Zorzino and Sandri, {Maria Teresa} and Edoardo Botteri and Fabrizio Verweij and Donatella Granchi and {De Cobelli}, Ottavio and Giovanni Paganelli",
year = "2008",
month = "5",
doi = "10.2174/156800908784293613",
language = "English",
volume = "8",
pages = "199--206",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer

AU - De Cicco, Concetta

AU - Ravasi, Laura

AU - Zorzino, Laura

AU - Sandri, Maria Teresa

AU - Botteri, Edoardo

AU - Verweij, Fabrizio

AU - Granchi, Donatella

AU - De Cobelli, Ottavio

AU - Paganelli, Giovanni

PY - 2008/5

Y1 - 2008/5

N2 - Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of patients if pre-surgical identification were available. Material and Methods: Correlations between pre-surgical levels of 6 blood molecules and pathological tumour staging, post-surgical Gleason score and disease-free survival have been observed. Plasma and sera from 162 men affected by prostate adenocarcinoma were analysed with ELISA to assess levels of neovascularization-related molecule (VEGF), endothelial cell adhesion molecule (VCAM), extracellular matrix destruction-related molecules (MMP-2, MMP-9), and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2). Results: The median values of serum determinations were for VEGF 279 pg/ml, VCAM 633 ng/ml, MMP-2 206 ng/ml and MMP-9 614 ng/ml. Plasma medians (ng/ml) were 94 for TIMP-1 and 90 for TIMP-2. Patients with VCAM values > 633 ng/ml had a worse disease-free survival than patients with values

AB - Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of patients if pre-surgical identification were available. Material and Methods: Correlations between pre-surgical levels of 6 blood molecules and pathological tumour staging, post-surgical Gleason score and disease-free survival have been observed. Plasma and sera from 162 men affected by prostate adenocarcinoma were analysed with ELISA to assess levels of neovascularization-related molecule (VEGF), endothelial cell adhesion molecule (VCAM), extracellular matrix destruction-related molecules (MMP-2, MMP-9), and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2). Results: The median values of serum determinations were for VEGF 279 pg/ml, VCAM 633 ng/ml, MMP-2 206 ng/ml and MMP-9 614 ng/ml. Plasma medians (ng/ml) were 94 for TIMP-1 and 90 for TIMP-2. Patients with VCAM values > 633 ng/ml had a worse disease-free survival than patients with values

KW - Blood marker

KW - Bone metastasis

KW - MMP

KW - MMP-2

KW - Prognosis

KW - Prostate cancer

KW - TIMP

KW - VCAM

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=43449086399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449086399&partnerID=8YFLogxK

U2 - 10.2174/156800908784293613

DO - 10.2174/156800908784293613

M3 - Article

C2 - 18473733

AN - SCOPUS:43449086399

VL - 8

SP - 199

EP - 206

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 3

ER -